

## *Division of Signal Transduction Therapy*

### **Standard Operating Procedure**

#### **Preparation of TIFA T9A T165A T177A [2 - 184]**

**Enzyme description:-** TIFA T9A T165A T177A [2 – 184]

**Clone number:-** DU 71092

**Source:-** Recombinant

**Expression system:-** *E.coli*

**Tag:-** N-terminal GST

**Purification method:-** GSH Sepharose

**Calculated molecular mass:-**

Monoisotopic 48, 016.83 daltons

Average Mass 48, 048.04 daltons

[cysteines reduced, methionines have not been oxidised

**Theoretical pI:-** 5.38

**Purity:-** >80 %

**Enzyme storage buffer:-**

50 mM Tris-HCl pH 7.5, 270 mM Sucrose, 150 mM NaCl, 0.1 mM EGTA,  
0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 1 mM benzamidine, 0.2 mM PMSF

**Storage temperature:-** -70 °C

*Division of Signal Transduction Therapy*

**Clone Data Sheet**

**TIFA T9A T165A T177A [2 – 184]**

<b><u>Protein</u></b>	TIFA T9A T165A T177A [2 – 184]
<b><u>Clone number</u></b>	DU 71092
<b><u>Species</u></b>	Human
<b><u>Accession number</u></b>	NM_052864.2
<b><u>Tags</u></b>	N-terminal GST
<b><u>Bacterially expressed protein</u></b>	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELG LEFPNLPPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAETSMLEGA VLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDH VTHPDFMLYDALDVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSS KYIAWPLQGWQATFGGGDHPPKSD <del>LEVL</del> <b>FQGP</b> <b>GSTSFEDAD</b> <b>A</b> <b>EETVTC</b> <b>LQMTVYHPGQLQCGIFQSI</b> <b>SFNREKLPSS</b> <b>EVVKFGRNSNICHYT</b> <b>QDKQ</b> <b>VSRVQFSLQLFKKFNSSVLSFEIKNMSKKTNLIVDSRELGYLNKMDLPY</b> <b>RCMVRFGEYQFLMEKEDGESLEFFETQFILSPRSLLQENNWP</b> <b>PHRPIPE</b> <b>YGAYSLCSSQSSPAEMDENES</b>
<b><u>Native sequence</u></b>	Amino acids T2 – S184 (end) of human TIFA. Residue T232 of the fusion protein is equivalent to T2 of the native enzyme. The GST tag is located at residues 1 – 220.
	The enzyme has an <b>T9A</b> , <b>T165A</b> and <b>T177A</b> mutation. Residue T9 is equivalent to <b>A239</b> of the fusion protein, residue T165 is equivalent to <b>A395</b> of the fusion protein and residue T177 is equivalent to <b>A407</b> of the fusion protein.
<b><u>Protease cleavage</u></b>	PreScission ( <b>LEVL</b> <b>FQGP</b> ) residues 221 - 228
<b><u>Cloning sites</u></b>	<i>Bam</i> H1 and <i>Not</i> 1 sites of pGEX6P-1

## *Division of Signal Tranduction Therapy*

### Complete Nucleotide Sequence

ATGTCCCCTATACTAGGTTATTGGAAAATTAAAGGGCCTTGTGCAACCCA  
CTCGACTTCTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTGTA  
TGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTGAATTGGGT  
TTGGAGTTCCCAATCTTCCTTATTATATTGATGGTATGTTAAATTAA  
CACAGTCTATGCCATCATACGTTATATAGCTGACAAGCACAACATGTT  
GGGTGGTTGTCCAAAAGAGCGTGCAGAGATTCAATGCTGAAGGAGCG  
GTTTGGAATTTAGATACGGTGTTCGAGAATTGCATATAGTAAAGACT  
TTGAAACTCTCAAAGTTGATTTCTTAGCAAGCTACCTGAAATGCTGAA  
AATGTTCGAAGATCGTTATGTCATAAAACATATTTAAATGGTGTGATCAT  
GTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTAT  
ACATGGACCCAATGTGCCTGGATGCGTCCAAAATTAGTTGTTTAA  
AAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGC  
AAGTATATAGCATGGCCTTGCAGGGCTGGCAAGCCACGTTGGTGGTG  
GCGACCACCTCCAAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCT  
GGGATCCACCAGTTGAAGATGCTGACGAGAAGACAGTAACTTGT  
CTCCAGATGACGGTTACCACCTGGCCAGTTGCAGTGTGGAATATTTC  
AGTCAATAAGTTAACAGAGAGAAACTCCCTCAGCGAAGTGGTGAA  
ATTTGGCCGAAATTCCAACATCTGTCAATTATACTTTCAGGACAAACAG  
GTTTCCCGAGTTCAAGTTCTGCAGCTGTTAAAAAATTCAACAGCT  
CAGTTCTCTCCTTGAATAAAAATATGAGTAAAAGACCAATCTGAT  
CGTGGACAGCAGAGAGCTGGGCTACCTAAATAAAATGGACCTGCCATAC  
AGGTGCATGGTCAGATTGGAGAGTATCAGTTCTGATGGAGAAGGAAG  
ATGGCGAGTCATTGAAATTGGACTCAATTATTTATCTCCAAG  
ATCACTCTGCAAGAAAACAACGGCCACCACAGGCCCATACGGAG  
TATGGCGCTTACTCGCTTGCTCCTCCAAAGCAGTCTCCGGCAGAAA  
TGGATGAAAATGAGTCAtga